Survival curves among 107 patients with relapsed T-NHL treated with DHAP/GDP in second-line. (A) 5-year OS and PFS curves are presented. (B) 5-year OS and PFS are presented for 33 patients who received autologous or allogeneic SCT after DHAP/GDP, using a landmark analysis.